Constance Keyserling
Operationeel Directeur bij ABIONYX PHARMA
Actieve functies van Constance Keyserling
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ABIONYX PHARMA | Operationeel Directeur | - | - |
| Corporate Officer/Principal | - | - |
Loopbaan van Constance Keyserling
Eerdere bekende functies van Constance Keyserling
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
| ESPERION THERAPEUTICS, INC. | Operationeel Directeur | - | - |
| Parke, Davis & Co. LLC | Corporate Officer/Principal | - | - |
QuatRx Pharmaceuticals Co.
 QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - | - |
Opleiding van Constance Keyserling
| Harvard University | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
| Frankrijk | 2 |
Operationeel
| Corporate Officer/Principal | 4 |
| Chief Operating Officer | 2 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ABIONYX PHARMA | Health Technology |
| ESPERION THERAPEUTICS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
QuatRx Pharmaceuticals Co.
QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Health Technology |
| Parke, Davis & Co. LLC |
